Pharmaceuticals

Revenue of the Live Attenuated Vaccines Market Predicted to Achieve $41.11 Billion by 2030, Driven by 9.6% CAGR

February 16, 2026February 16, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the live attenuated vaccines market from 2026–2035 with trusted insights from The Business Research Company

How much is the Live Attenuated Vaccines Market valued at in 2026, and what valuation is forecast for 2030?

The live attenuated vaccines market size has observed significant growth in recent years. It is anticipated to increase from $25.95 billion in 2025 to $28.52 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.9%. This past growth can be attributed to the global burden of infectious diseases, governmental immunization campaigns, childhood vaccination policies, hospital-based vaccine provision, and World Health Organization (WHO) vaccination programs.

The live attenuated vaccines market is projected to experience robust expansion in the upcoming years. This market is forecast to reach a value of $41.11 billion by 2030, driven by a compound annual growth rate (CAGR) of 9.6%. Key factors contributing to this anticipated growth include an increased demand for booster vaccinations, the emergence of new infectious disease risks, enhancements in cold chain infrastructure, augmented global health funding, and the development of next-generation vaccine platforms. Significant trends expected during this forecast timeframe encompass the broadening of national immunization initiatives, a rising need for pediatric vaccinations, improvements in vaccine stability and storage solutions, a heightened emphasis on pandemic readiness, and the progression of multivalent vaccine development.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24590&type=smp

What Drivers Are Influencing The Growth Of The Live Attenuated Vaccines Market?

The escalating occurrence of infectious diseases is anticipated to boost the expansion of the live attenuated vaccines market going forward. Infectious diseases are ailments resulting from detrimental microorganisms such as bacteria, viruses, fungi, or parasites, capable of transmitting directly or indirectly between individuals, animals, or environments. Enhanced global travel exacerbates the dissemination of infectious diseases, enabling pathogens to traverse boundaries more rapidly than containment efforts. Live attenuated vaccines contribute to preventing these diseases by eliciting a robust immune response through weakened pathogens, thereby guaranteeing lasting immunity and diminishing disease transmission. For instance, in March 2025, according to the World Health Organization, a Switzerland-based intergovernmental organization, in 2023, an estimated 10.8 million people fell ill with TB worldwide, including 6.0 million men, 3.6 million women, and 1.3 million children. Consequently, the rising incidence of infectious diseases is fueling the growth of the live attenuated vaccines market.

How Is The Live Attenuated Vaccines Market Organized Into Various Segments?

The live attenuated vaccines market covered in this report is segmented –

1) By Vaccine Type: Monovalent, Multivalent

2) By Route Of Administration: Intramuscular, Subcutaneous, Oral Attenuated, Intranasal Attenuated

3) By Indication: Influenza, Measles, Mumps and Rubella (MMR), Polio, Chickenpox, Shingles, Rotavirus, Other Indications

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Clinics, Diagnostic Centers, Research Institute, Other End-Users

Subsegments:

1) By Monovalent: Single-Dose Vaccines, Multiple-Dose Vaccines

2) By Multivalent: Bivalent Vaccines, Trivalent Vaccines, Quadrivalent Vaccines, Other Multivalent Vaccines

What Upcoming Trends Are Likely To Define The Future Path Of The Live Attenuated Vaccines Market?

Leading companies operating within the live attenuated vaccines market are directing their efforts towards developing advanced products, such as single-dose vaccines, to improve immunization efficiency and enhance patient compliance. Single-dose vaccines offer lasting immunity with a single shot, thereby removing the necessity for multiple doses. This simplifies the vaccination process for both patients and healthcare providers, increasing convenience and accessibility. For example, in November 2023, Valneva SE, a France-based biotech company specializing in vaccines for infectious diseases, announced the launch of IXCHIQ, which had received approval from the U.S. Food and Drug Administration (FDA), a US-based health agency. This product represents the world’s first live-attenuated chikungunya vaccine specifically indicated for adults aged 18 and older. This approval holds significant importance as IXCHIQ is the world’s first licensed vaccine for chikungunya, addressing an unmet medical need for protection against this mosquito-borne viral disease, which is known to cause severe fever, joint and muscle pain, and various other symptoms.

Who Are The Core Companies Influencing Trends In The Live Attenuated Vaccines Market?

Major companies operating in the live attenuated vaccines market are Merck & Co. Inc., Sanofi SA, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, CSL Limited, GC Biopharma, Serum Institute of India Pvt. Ltd., Bavarian Nordic, Valneva SE, Southern Research, BioFarma, Bharat Biotech International Limited, Meissa Vaccines Inc., BioDiem Ltd., Bio-Med Limited, Naobios, Lakshmi Pharmaceuticals

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/live-attenuated-vaccines-global-market-report

Which Regions Are Projected To Dominate The Live Attenuated Vaccines Market In The Coming Years?

North America was the largest region in the live attenuated vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the live attenuated vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Live Attenuated Vaccines Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24590&type=smp

Browse Through More Reports Similar to the Global Live Attenuated Vaccines Market 2026, By The Business Research Company

Inactivated Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/inactivated-vaccines-global-market-report

Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

Veterinary Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/veterinary-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795